However, there are exceptions where it is preferable to use paternally inherited polymorphisms to confirm the presence of fetal DNA instead of detecting methylated RASSF1A. Several recent studies have reported that aberrant methylation in the promoter region of RASSF1A can also be used as potential marker for (early) diagnosis of several types of cancer [34]–[36]. Here, RASSF1 is linked to cancer.